HHS purchases 100 million additional doses of Moderna COVID-19 vaccine candidate
The Department of Health and Human Services Dec. 11 announced it would purchase from Moderna 100 million additional doses of its mRNA-1273 COVID-19 vaccine candidate.
The candidate, which was co-developed by Moderna with scientists from the National Institute of Allergy and Infectious Disease, is slated for a Dec. 17 review by the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee. The vaccine requires two doses, administered 28 days apart.
The purchase doubles the amount of Moderna vaccine owned by the federal government, to 200 million.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…